Member Info for Laura2022

Uncanny

So I assume you will continue on the sidelines?

Surely , you can't be invested with the amount of doubts you've presented over the last few months ?

Come a cropper

Thanks

The green boxes are getting so desperate

On here, SFOR PFC etc

You wonder their motivation

Charts have bottomed and consolidation last 3 days

The main breakout technically should be late this week

Thanks msuk

Have you got an up to date one please

Would be a good start

Morning all

On VAL porky has accused me of being 4 different people (riddler , PM2022,SEawolf and one other)

Now i see people are trying to discredit me

I have no idea who PM2022,riddler or Seawolf are

On WG discussoon they've accused of working for a "ramping" group

Social media is a horrible toxic masculine place at times

£100mln+ debt

As at 30 June 2024, the Company had unaudited total liabilities of approximately of £143.1 million and net liabilities of approximately £116 million

Rocket/ping

It seems like across the exploration sector shareholders are finally holding the corrupt BODs.to account

COPL VAST PREM RRR etc

Not before time

Loch

Thanks for this

This could be one of the best risk- reward mid caps on offer at the moment with a little more patience than a day or 2 .

Congratulations to Ankyra Therapeutics on dosing the first visceral tumour patient in the Phase 1 ANCHOR trial for ANK-101! 🎉 It’s great to see another project Physiomics plc has supported continue to progress in clinical development.

We’re proud to have worked with Ankyra on building a preclinical PK-TGI model describing PK and Tumour Growth Inhibition data across various studies for the ANK-101 murine surrogate (mANK-101). This model offered valuable insights that could inform clinical decision-making for ANK-101.

Check out our poster detailing this work: https://lnkd.in/enr34fBE

KingH etc

What is telling for me is the BOD here take the lowest wages on AIM , they take about 1/4 of average cess pit AIM company and also companies that aren't even growing yet alone generating revenues. As you also state KingH PYC debt free and could be cash generative within 12mths if the current revenues progression continues as it has done under the new CEO

No wonder someone wanted 2.5% PYC 2 Fridays ago

1) very low salaries...eg £70k CEO v £300K Ceo like WSG

2) low overheads

3)growing revenues

4) growing pipeline

5) cashed up

6] growth markets of drug discovery and biostatistics

7]potential for large uplifts..eg if VAL201 comes in or personalised dosing app takes off in America

7) very low shares in issue (only 230mln)

Looks like at £350mln cap with free cash flow and asset sales of $125mlm due to complete next 1-2mths and NAV of probably £1.50+ and now charts MACD/RSI turning positive

Bring the bidders

See my question /summary last month

Some CLNS finer details in the results...may be that

Buying has started

I'd imagine we'll get an update shortly about new initiatives and potential JVs as suggested in various RNS recently

Eg Biostatistics JV/partners

Eg DoseMeRx JV potential or standalone business for the A.I dosing app

Looks like the jekyll and hydes are getting desperate judging by the green boxes

No I'm not

But you call placings on every stock but never call it on ones you ramp

Funny that

What about EME TRP CPX for u ?

He's done more in 6mths than Suzy and previous CEO combined

AND actually has a shareholding

He comes across very well